Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$0.22.

  • Anika Therapeutics' EPS (Basic) rose 8916.26% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6505.14%. This contributed to the annual value of -$3.83 for FY2024, which is 3209.22% up from last year.
  • Per Anika Therapeutics' latest filing, its EPS (Basic) stood at -$0.22 for Q3 2025, which was up 8916.26% from -$0.33 recorded in Q2 2025.
  • Anika Therapeutics' 5-year EPS (Basic) high stood at $0.45 for Q2 2021, and its period low was -$4.3 during Q4 2023.
  • Its 5-year average for EPS (Basic) is -$0.59, with a median of -$0.31 in 2024.
  • Per our database at Business Quant, Anika Therapeutics' EPS (Basic) soared by 18333.33% in 2021 and then crashed by 116470.59% in 2023.
  • Quarter analysis of 5 years shows Anika Therapeutics' EPS (Basic) stood at -$0.4 in 2021, then rose by 15.0% to -$0.34 in 2022, then tumbled by 1164.71% to -$4.3 in 2023, then surged by 65.35% to -$1.49 in 2024, then skyrocketed by 85.23% to -$0.22 in 2025.
  • Its EPS (Basic) was -$0.22 in Q3 2025, compared to -$0.33 in Q2 2025 and -$0.34 in Q1 2025.